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httpcense.Abstract Background: Urinary lipoarabinomannan (LAM) detection is a promising approach for
the rapid diagnosis of active tuberculosis (TB).
Objective: To assess the diagnostic accuracy of urine LAM among TB patients either pulmonary
or extra pulmonary.
Methods: This study was carried out on 85 cases (46 male and 39 female) with active tubercular
infection divided into three groups; pulmonary (n= 40), extra pulmonary (n= 30) and dissemi-
nated tuberculosis (n= 15). Twenty-ﬁve normal individuals were included as the control group.
LAM level was measured in urine by enzyme-linked immunosorbant assay (ELISA).
Results: TB Patients with disseminated disease had a higher urine LAM level (1.75 ± 1.65 ng/
ml) than that for patients with pulmonary (0.58 ± 0.53 ng/ml) or extra pulmonary TB
(0.17 ± 0.11 ng/ml) (P< 0.001). Patients with smear positive specimens had a higher urine
LAM level (0.63 ± 0.54 ng/ml) than that of smear negative (0.040 ± 0.06 ng/ml) (P< 0.001).
Quantitative urine LAM test results positively correlate with the degree of bacillary burden.
Advanced age, immunosuppressant state and advanced radiological lesion were signiﬁcant factors
that were associated with higher quantitative urine LAM (P< 0.05).
Conclusion: Urine LAM test is a simple, rapid, and reliable diagnostic modality for active
pulmonary or extra pulmonary tuberculosis. Quantitative LAM detection results increasedest Department, Menouﬁya
le: +20 1004774422.
oo.com (M.A. Agha).
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402 M.A. Agha et al.progressively with bacillary burden and immunosuppression. Patients with disseminated TB are tar-
get populations for urine LAM detection.
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It is estimated that 2 billion of the world’s population are la-
tently infected with Mycobacterium tuberculosis (MTB) with
a resultant 8–9 million cases of active tuberculosis (TB) and
1.6 million deaths annually [1]. Despite the fact that low-in-
come and middle-income countries account for over 90% of
the worldwide burden of TB, these regions still rely heavily
on sputum smear microscopy and chest radiology for TB diag-
nosis. These techniques often perform poorly and are typically
unavailable at patients’ ﬁrst point of contact with the health
system. Moreover, the diagnostic accuracy of these techniques
is substantially impaired in those with HIV co-infection [2].
Current TB diagnostics, TB skin testing (TST), sputum smear,
culture and radiology have remained the mainstay of TB diag-
nostics since 1882. TST has been used to support the diagnosis
of TB in populations where TB infection is low. TST is how-
ever still a useful tool for epidemiological studies of the annual
risk of infection in children. In industrialized countries the
TST identiﬁes a minority of individuals who are at increased
risk of disease progression, to whom diagnostic and preventive
resources can be targeted [3]. In contrast, in those with ad-
vanced HIV infection, who are at highest risk of disease pro-
gression, the test has low sensitivity with up to 50% false
negatives [3]. Sputum smear microscopy has high speciﬁcity
in high TB prevalence settings. Sputum microscopy has been
the mainstay of TB control programs as it is able to identify
the most infectious cases. The test is relatively inexpensive
and widely available [4]. However, the sensitivity for diagnos-
ing pulmonary tuberculosis using direct sputum smear meth-
ods ranges from 40% to 60%. Additionally, sputum smear
cannot be used for persons who cannot produce sputum such
as children and those with extra pulmonary disease [5]. Solid
media culture, however, is limited by the prolonged time re-
quired for positive and negative results, which can be delayed
for 6–8 weeks. Culture of sputum has low sensitivity for extra-
pulmonary TB, which occurs more commonly in HIV-infec-
tion [6]. Delayed diagnosis facility, disease transmission,
increases healthcare costs, and increases in mortality, cause
greater lung damage resulting in chronic disability [7]. LAM
is a cell wall lipopolysaccharide speciﬁc for the genus Myco-
bacterium. LAM is a 17.5-kDa glycolipid component of the
mycobacterial cell wall. It is synthesized when amannopyr-
anosyle adds to a phosphoinositol to produce PIMs and lipo-
mannan (LM). PIM and LM are then glycosylated with
arabinan to form LAM. LAM is one of three major groups
of interrelated lipopolysaccharides within the mycobacterial
cell wall [8]. All these molecules are non-covalently attached
to the mycobacterial plasma membrane via the glyco-phospho-
lipid anchor and extend to the surface of the cell wall. LAM
molecules have three major structural domains. The phospho-
lipid anchor is linked to a carbohydrate (mannose core, which
is conserved across all mycobacterial species, and from this
carbohydrate (arabinofuranosyl) side-chains arise [8]. Variablecapping of the arabinosyl side-chains with mannose residues
results in a diversity of LAM molecules with a range of unique
properties and functions. LAM is released when Mycobacte-
rium tuberculosis is lysed by the host immune system ﬁltered
by the kidneys and can be detected in the urine as a potential
same day diagnostic test for tuberculosis. Urinary LAM con-
centrations may be a reﬂection of infecting MTB individuals
[9].
Patients and methods
Eighty-ﬁve patients with conﬁrmed active mycobacterial tuber-
culosis out of 120 cases were recruited from Chest Depart-
ments in the Minouﬁya University hospital, Egypt; during
the period from July 2012 to April 2013. They were divided
into three groups; Pulmonary (n= 40), Extra pulmonary
(n= 30) and Disseminated tuberculosis group (n= 15).
Twenty-ﬁve normal individual were included as the control
group. Eligibility criteria were kept broad to capture the full
spectrum of pulmonary and extra pulmonary TB suspects.
Inclusion criteria for the LAM diagnostic study component
were ageP 18 years, conﬁrmed cases of TB, urine sample
available for testing, and informed consent. Patients who were
on TB therapy were excluded. Ethical research approval from
our hospital’s ethics committee and informed consent from the
patients were obtained. Searching to deﬁne diagnostic criteria
for tuberculosis all participants were initially identiﬁed by:
Complete history taking, thorough general and local chest
examination, Body mass index (BMI) was calculated as:
Weight in kilograms/Height in square meters. Roentographic
investigation was done (Chest X-ray P–A and lateral views)
and CT of chest if needed). Venipuncture with measurement
of Routine laboratory investigation: Complete blood count
(CBC). Erythrocyte sedimentation rate (ESR), liver and kid-
ney functions tests, and fasting blood sugar. Resting arterial
blood gases were measured during room-air breathing using
ABL 3 Blood gas analyzer, Radiometer, Copenhagen, Den-
mark. Tuberculin skin test (standard dose of Tuberculin units
(0.1 mL) was injected intradermally and read 48 to 72 h later,
Positive tuberculin test was indicated if the indurated area was
10 mm or more in diameter). Three successive morning sputum
samples were collected in a leak-proof, sterile container. Initial
processing of specimens consisted of concentration and decon-
tamination using 4% NaOH. From the sediment Ziehl-neelsen
(ZN) smears done and Lowenstein Jensen (LJ) tubes are inoc-
ulated. Following the three successive early morning sputum
samples that had been proved to be negative for AFB or when
the sputum cannot be obtained, the patient was subjected to a
Fiber-optic bronchoscope (Pentax FB, 19-TV, with internal
diameter of 2 mm) and the samples were sent to both ZN stain
and LJ culture. In cases of suspicion of tuberculosis pleural
effusion thoracentesis, or pleural biopsy was undergone, ﬁne
needle aspiration of a lymph node or tissue biopsy was also
done in suspected cases.
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bacterial culture positive for mycobacterial tuberculosis were
determined to have conﬁrmed TB and were included in the
current analysis.
 Pulmonary tuberculosis was deﬁned as the presence of one
or more sputa positive for AFB by microscopy and/ or posi-
tive for mycobacterium tuberculosis by culture.
 Localized extra pulmonary TB was deﬁned as the isolation
of M. tuberculosis from, ﬁne needle aspiration of a lymph
node or tissue biopsy but not from any other respiratory
specimens. Tuberculous pleuritis was deﬁned as one or
more of the following criteria: mycobacteria or caseating
granuloma detected on pathological examination of pleural
biopsy, positive mycobacterial ZN stain from the pleural
ﬂuid.
 Individuals with M. tuberculosis isolated from both pul-
monary and extra-pulmonary specimens were considered
to have disseminated disease.
Radiological classiﬁcation of disease extent was: I-Minimal:
where slight to moderate density was demonstrated but with-
out remarkable cavitations, it involved a small part of one or
both lungs. II-Moderately advanced: slight to moderate den-
sity not exceeding the total volume of one lung or the equiva-
lent in both lungs or dense lesion limited in extent to one-third
of lung volume and total diameter of cavitations were, less
than 4 cm. III-Far advanced (Lesions more extensive than
moderately advanced). Immune-suppression among TB pa-
tients was deﬁned in participants under long term of cortico-
steroid or chemotherapy, and those on dialysis, addict, or a
participant with uncontrolled diabetes.
Urine samples will be taken from all diagnosed cases and
the healthy control and sent for ELISA for the detection of
LAM [10].
Measurement of LAM
Within 72 h of enrolment, a random 2 mL sample of urine was
collected in a sterile plastic container and stored at 2–8uC
within four hours for up to 24 h before freezing or processing.
Lipoarabinomannan was measured in urine by ELISA (Hu-
man LAM ELISA kit. (Glory science). The kit uses Puriﬁed
Human LAM antibody to coat microtiter plate wells, make so-
lid-phase antibody, then added LAM to the wells. Combined
LAM antibody with which the enzyme was labeled, becomes
the antibody–antigen–enzyme-antibody complex. After wash-
ing completely, substrate was added and the substrate becomes
blue in color In the HRP enzyme-catalyzed reaction, the reac-
tion is terminated by the addition of a sulphuric acid solution
and the color change is measured spectrophotometrically at a
wavelength of 450 nm. The concentration of LAM in the sam-
ples is then determined by comparing the O.D. of the samples
to the standard curve [10].
Quantitative urine LAM test results were expressed as opti-
cal density (OD) readings. The ﬁnal sample OD was deter-
mined by subtracting the OD of the negative control from
the sample reading, with a minimum value of 0 (i.e. a value
of 0 was reported if the OD of the negative control was greater
than the OD of the sample). An OD above 0.1 was considered
positive as per manufacturer speciﬁcations. Multiple linearregression models were used to determine predictors of higher
qualitative urine LAM test results.
Data were collected, tabulated, statistically analyzed by
computer using SPSS version 16, two types of statistics were
done:
1-Descriptive statistics
Quantitative data are expressed to measure the central ten-
dency of data and diversion around the mean, mean (x) and
standard deviation (SD).
Qualitative data are expressed in number and percentage.
2- Analytic statistics
 Krauskal Wallis test was used for the comparison of more
than two groups of non-normally distributed variables;
mann whitney test was used to compare between two
groups of quantitative data not normally distributed; ﬁscher
exact test and chi-square (x2) tests were used to compare
categorical outcomes.
 Pearson correlation (r) was used to detect the association
between quantitative variables.
Sensitivity, speciﬁcity, positive and negative predictive va-
lue, and diagnostic accuracy were calculated according to the
following formula:
Sensitivity ¼ a=ðaþ cÞSpecificity ¼ d=ðbþ dÞAccuracy
¼ ðaþ dÞ=ðaþ bþ cþ dÞNegative value
¼ d=ðcþ dÞPositive predictive value ¼ a=ðaþ bÞ
where a = true positive cases; b = false positive cases;
c = false negative cases; d = true negative cases. All these
tests were used as tests of
 Signiﬁcance:
*P value > 0.05 was considered statistically non-signiﬁcant.
*P value 6 0.05 was considered statistically signiﬁcant.
*P value 6 0.001 was considered statistically highly
signiﬁcant.
Results
Overall 120 participants suspected to have TB, 85/120 (66.6%)
had conﬁrmed TB. Mycobacterial isolates were recovered from
the culture of respiratory or non-respiratory specimens in 75/
85(85.9%) and 71/85(83.5%) with positive acid fast bacilli
(AFB) smear, however caseating granuloma of TB could be
detected via histopathological analysis of tissue biopsy in 10/
85(11.7%) subjects. Among the conﬁrmed TB cases 46/
85(54%) were male and 39/85(46%) female. And 48/
85(56.4%) were immuncompromized at the time of enroll-
ment. TB manifestation ranged from localized to disseminated
disease. I-Localized extra pulmonary TB was diagnosed in 30/
85(35.2%) cases, (thirteen out of thirty participants had M.
tuberculosis isolated from pleural cultures, 12/30 hadM. tuber-
culosis isolated from a lymph node. 2/30 were isolated from
Figure 1 Pearson correlation between age and LAM values.
404 M.A. Agha et al.intervertebral lumber discs in Potts disease, and one/thirty
from each of the following: laryngeal nodules, ascetic ﬂuid
and knee abscess). II-Pulmonary TB in 40/85(47.05%) cases,Table 1 Predictors of high urinary LAM.
LAM positive 69
Age
<40 11 15.9
40–60 33 47.8
>60 25 36.2
Sex
Male 39 56.5
Female 30 43.5
Type of TB:
Pulmonary(n= 40) 30 43.4
Extrapulmonary (n= 30) 24 34.7
Disseminated (n= 15) 15 21.7
BMI > 18 (n= 40) 29 42
BMI < 18 (N= 45) 40 58
Risk factors
Immunocompromized N= 48 44 63.7
Immunocompitant N= 37 25 36.3
Tuberculin positive n= 46 40 58
Tuberculin negative n= 39 29 42
CXR for pulmonary TB
Mild n= 25 15 21.7
Moderate advanced n= 30 26 37.7
Far advanced n= 30 28 40.6
Sputum smear +ve (n= 71) 62 89.9
Sputum smear ve (n= 14) 7 10
Positive culture (n= 75) 67 97.1
Negative culture (n= 10) 2 2.9
Mortality at 2 months n= 7 6 8.7
Survival n= 78 63 91.3
ﬁ – Fischer’s exact test, H – highly signiﬁcant test, S – signiﬁcant test.III-disseminated disease in 15/85(17.6%) cases. Ten normal
individuals were included as the control group. The LAM anti-
gen binds with optimal concentration of Anti-LAM antibodyLAM negative 16 Chi square test P-Value
6 37.6 7.02 <0.05*S
9 56.2
1 6.2
7 43.8 0.853 >0.05
9 56.2
10 62.5 4.5 >0.05
6 37.5
0 0
11 68.75 3.72 >0.05
5 31.25
4 25 4.12 <0.05*S
12 75
6 37.5 2.19 >0.05
10 43.75
10 43.75 3.14
4 25
2 12.5 <0.05*S
9 56.25 10.83 ﬁ <0.05*S
7 43.75
8 50% 35.84 ﬁ <0.001*H
8 50%
1 6.25 0.1 ﬁ >0.05
15 93.75
Table 3 Grading of sputum smear and LAM values.
Sputum ZN smear positive (n= 71) GRADE1+ N= 13 Grade2+ N= 15 Grade 3+ N= 43 Kruskal wallis test P Value
X ± SD of LAM 0.31 ± 0.43 0.77 ± 0.56 0.84 ± 0.49 10.37 <0.01*H
ZN – Zeihl Nelseen, LAM – Lipoarabinomannan, H – highly signiﬁcant test.
Table 4 Positivity of the sputum smears and LAMS values.
Sputum ZN smear
microscopy status
Sputum ZN smear Positive
n= 71
Sputum ZN smear Negative
n= 14
Mann
whitney
P Value
X ± SD of LAM 0.63 ± 0.54 0.040 ± 0.06 7.18
<0.001*H
ZN – Zeihl Neelsen, LAM – lipoarabinomannan.
Table 5 Validity of urine LAM test, ZN for AFB smear, and both methods in detecting positive cases of TB in conﬁrmed TB cases.
Validity Urine LAM (%) ZN for AFB smear (%) Combined methods for M.TB (%)
Sensitivity 81.2 83.5 88.2
Speciﬁcity 95.7 100 100
Accuracy 86.4 89.2 92.3
PPV 97.2 100 100
NPV 73.8 76.2 81.8
PPV= positive predictive value; NPV= negative predictive value.
Table 2 Type of TB and LAM values.
TB type Extra
pulmonary
n= 30
Pulmonary
n= 40
Disseminated
n= 15
Value of the
signiﬁcance test
Test of
signiﬁcance
P Value
X ± SD of age 47.30 ± 11.16 50.97 ± 13.61 53.93 ± 10.51 1.61 ANOVA >0.05
X ± SD of LAM 0.17 ± 0.11 0.58 ± 0.53 1.75 ± 1.65 21.89 Kruskal wallis <0.001*H
Gender 16M (53.5%) 22M (55%) 8M (53.3%) 0.02 Chi square >0.05
Male/female 14F (46.5%) 18F (45%) 7F (46.6%)
Smoking 6 (20%) 10 (25%) 4(26.6%) 0.43 Chi square >0.05
DM 5 (16.6%) 12(30%) 6 (40%) 4.61 Chi square >0.05
On corticosteroid or chemotherapy 10(33.3) 10(25%) 5(33.3%) 0.71 Chi square >0.05
TST positive 16(53.3%) 22(55%) 8(53.3%) 0.02 Chi square >0.05
Smear positive 25(83.3%) 31(77.5%) 15(100%) 4.02 Chi square >0.05
TB culture positive 20(66.6%) 40(100%) 15(100%) 20.78 Chi square <0.001*H
Toxic symptoms 18(60%) 22(55%) 9(60%) 0.22 Chi square >0.05
Utility of quantitative analysis of urine lipoarabinomannan in the diagnosis of tuberculosis 405from the urine in 69 out of 85 cases of active pulmonary and
extra pulmonary TB. Patients with disseminated disease had
a higher urine LAM level (1.75 ± 1.65 ng/ml) than that for pa-
tients with pulmonary (0.58 ± 0.53 ng/ml) or extra pulmonary
TB (0.17 ± 0.11 ng/ml) (P< 0.001). Patients with smear posi-
tive specimens had a higher urine LAM level (0.63 ± 0.54 ng/
ml) than that of smear negative (0.040 ± 0.06 ng/ml)
(P< 0.001). Quantitative urine LAM test results positively
correlate with degree of bacillary burden in patients with
microbiologically conﬁrmed TB, it was higher in high inocu-
lums specimens (0.84 ± 0.49 ng/ml). Multiple linear regression
models were used to further explore factors associated with
higher quantitative urine LAM test results. Individuals with
advanced age, far advanced radiological lesion, and smear po-
sitive TB had higher quantitative urine LAM test (P< 0.05)Further, the absolute urine LAM test increased dramatically
as immuno-suppression progressed among TB patients. No
other covariates were signiﬁcantly associated with higher
quantitative urine LAM test results. Urine LAM test had sen-
sitivity, speciﬁcity, PPV, NPV, and an accuracy of 81.2%,
95.7%, 97.2%, 73.8%, and 86.4% respectively (see Fig. 1
and Tables 1–5).
Discussion
Overall, 120 participants suspected to have TB, 85/120
(66.6%) had conﬁrmed TB. The aim of this work was to assess
the diagnostic accuracy of urine LAM among tuberculous-in-
fected patients either pulmonary or extra pulmonary. In the
present work advanced age, depressed immune state, febrile
406 M.A. Agha et al.illness, smear and culture positivity, and the extensive radio-
logical lesions (regarding pulmonary TB) were signiﬁcant pre-
dictors that were associated with positive qualitative urine
LAM (P< 0.05). Robin and his colleagues [11] had explored
pathogen and host factors potentially impacting LAM detec-
tion. They reported that 32/199 (16.1%) of patients tested
LAM-ELISA was positive. LAM was associated with positive
sputum smear, culture, and declined host immune factors with
low CD4 cell counts. Median optical density and proportion
testing LAM positive remained unchanged during 2 weeks of
treatment and then declined over 24 weeks.
In the present work we found increased sensitivity of the
LAM test in advanced immune suppression, a ﬁnding which
is consistent with previous studies [11–13]. Shah et al. [12] also
reported that, HIV-infection, mycobacteremia, and positive
sputum smear were risk factors for a positive LAM test. More-
over Shah et al. [13] concluded that HIV-infected TB suspects
with advanced immunosuppression, a group in which sputum
microscopy is of low yield, may be a target population for
whom the urine LAM test would be particularly useful as they
found that among HIV-infected patients, individuals with CD4
counts of <50 had an average OD that was 1.05 OD units
higher than that for individuals with CD4 counts of >150
(P < 0.0001). Also, Lawn SD [14] postulated that this assay
has useful sensitivity for the diagnosis of HIV-associated TB
in patients with advanced immunodeﬁciency. Wood et al.
[15] stated that urinary LAM is related to host immune factors.
Our study revealed that patients with disseminated disease
had a higher urine LAM level (1.75 ± 1.65 ng/ml) than that
for patients with pulmonary (0.58 ± 0.53 ng/ml) or extra pul-
monary TB (0.17 ± 0.11 ng/ml) (P < 0.001). However Shah
et al. [13] found that among participants with conﬁrmed TB,
there was a signiﬁcant difference in median OD for those with
more localized disease compared to those with disseminated
disease (P< 0.0001) and the median OD increased progres-
sively from 0.01 to 0.13 to 0.64 to 1.4 in those with localized
extrapulmonary TB, PTB alone, mycobacteremia without
PTB, and combined PTB with mycobacteremia, respectively.
While Wood et al. [15] stated that LAM positive was not sta-
tistically related to the type of tuberculosis either pulmonary or
extra pulmonary but depended mainly on the immune status.
Also, Dheda et al. [16] found that the diagnostic usefulness
of urine-LAM is limited, as a rule-in test, to a speciﬁc patient
subgroup.
Our data revealed that Patients with smear positive spec-
imens had a higher urine LAM level (0.63 ± 0.54 ng/ml) than
that of smear negative (0.040 ± 0.06 ng/ml) (P< 0.001).
Quantitative urine LAM test results positively correlate with
degree of bacillary burden in patients with microbiologically
conﬁrmed TB, it was higher in high inoculums specimens
(0.84 ± 0.49 ng/ml). In accordance with Shah et al. [13]
who stated that there was a trend toward higher OD with
increasing grades of smear positivity (median ODs of 0.13,
0.18, 0.26 and 0.38 for smear-negative, smear-positive grade
1+, smear-positive grade 2++, and smear-positive grade
3+++ cases, respectively) and individuals with smear-
positive pulmonary TB had an average OD that was 0.33
OD units higher than that for individuals with smear-negative
pulmonary TB.
Urine LAM test had sensitivity, speciﬁcity, PPV, NPV, and
an accuracy of 81.2%, 95.7%, 97.2%, 73.8%, and 86.4%
respectively. In another study [17] sensitivity and speciﬁcityof a positive LAM for culture-conﬁrmed tuberculosis were
65% and 86% respectively, compared to the sensitivity and
speciﬁcity of sputum smear for culture conﬁrmed TB that
was 36% and 98% for sputum smear respectively. LAM sensi-
tivity was higher and speciﬁcity lower. The LAM test charac-
teristics that were identiﬁed in the present study were
consistent with those described in a systematic review of seven
studies that assessed test accuracy using only microbiologically
conﬁrmed cases (such as ours): sensitivity was 13%–93% and
Speciﬁcity 87–99%. Also Boehme and colleagues [18] used a
prior version of the existing urine LAM assay (Chemogen,
South Portland, Maine) to evaluate 231 TB suspects (69%
HIV-positive) and 103 healthy controls in Tanzania. Sensitiv-
ity was 80.3% among individuals with Talbot et al. [19] also
supported the role of urine LAM in the diagnosis of tubercu-
losis as they found among 69 cases of sputum or blood culture-
conﬁrmed tuberculosis, LAM sensitivity was 65% and speciﬁc-
ity 86% compared to 36% and 98% for the sputum smear.
Differences in test characteristics may relate both to different
LAM testing methodologies and different patient populations.
In the systematic review pooled sensitivity estimates from the
two studies that evaluated the early prototype version of the
test were signiﬁcantly higher than estimates from studies that
used either of the two commercial assays. Urine collection
and processing may inﬂuence accuracy, although analysis of
sub-groups in which the urine used in the assay was either fresh
or previously frozen found no statistically signiﬁcant differ-
ences between these groups. In our study, most assays were
conducted on frozen samples and we had too few results on
fresh samples for comparison.
In our study the combination of sputum smear plus LAM
testing identiﬁed 88.2% of conﬁrmed TB cases. Shah et al.
[13] in their work reported that, the LAM test was more
sensitive than sputum smear microscopy (42%, 82/193,
p< 0.001) and detected 56% (62/111) of those who were
sputum smear-negative. And the combination of urine LAM
testing and sputum smear microscopy identiﬁed 75% of
conﬁrmed TB cases.Conclusions
Our ﬁnding showed that the urine LAM test is simple, rapid,
and reliable diagnostic modality for active pulmonary or extra
pulmonary tuberculosis. Quantitative LAM detection results
increased progressively with bacillary burden. Usage of quan-
titative urine LAM test results may thus offer additional clin-
ical insight into the degree of TB disease severity that cannot
be gleaned from qualitative results alone. Patients with dissem-
inated TB are target populations for urine LAM detection.
The combination of LAM testing and sputum smear micros-
copy may have an additive beneﬁt in the TB group, while
the urine LAM test is unlikely to stand alone for deﬁnitive
TB diagnostic testing. Urine LAM can be a helpful diagnostic
method in patients with smear negative TB or in those with un-
accessible tissue biopsy. Measuring LAM in other body ﬂuids
as in BAL, sputum and blood need to be further investigated.
Qualitative and quantitative estimations of urine LAM may
have future utility as biomarkers reﬂecting response to TB
treatment. Further studies will be required to compare LAM
and TB-Gold (Quantiferone) especially for extra-pulmonary
TB infections.
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